Pharmaceutical Pricing in Malaysia



Malaysia’s healthcare system consists of two sectors namely public and private sector. Ministry of Health (MOH) is the main agency providing healthcare services in public sector.

Malaysia pharmaceutical market is dominated by prescription drugs that account for approximately 60 % of the pharmaceutical market share by value. There is no price control mechanism for pharmaceuticals in Malaysia. In fact, drug prices are not regulated in Malaysia and it is left to market forces to foster competition. However, in public sector, few price control strategies are employed by MOH to ensure fair, reasonable, affordable and stable prices of drugs. Despite various strategies formulated, there are challenges that need to be addressed. In public sector, the main challenges include escalating cost of pharmaceuticals as a result of privatization of Government Medical Store, lack of implementation of pro-generics policies and overlapping role of Malaysian Health Technology Assessment (MaHTAS) and Pharmacoeconomic Unit at Pharmaceutical Service Division (PSD) in cost-effectiveness evaluation of drugs. Similarly, in private sector, majority of the private health care providers would not follow the recommended retail price in selling medicines. In conclusion, there are several challenges that need be addressed in order to have a good pharmaceutical pricing strategy in Malaysia.


Community Pharmacy Generic Medicine Private Health Insurance Medicine Price International Reference Price 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Abdul LS (1999) Regulations and policies on pharmaceuticals in Malaysia: its impact on healthcare. Kaohsiung J Med Sci 15:S75–S78Google Scholar
  2. Asia Pacific Observatory on Health Systems and Policies (2013) Malaysia health system review [Online]. Accessed 20 Nov 2013
  3. Azmi IM, Alavi R (2001) TRIPS, patents, technology transfer, foreign direct investment and the pharmaceutical industry in Malaysia. J World Intellect Prop 4:946–976Google Scholar
  4. Babar ZUD, Izham MIM, Singh H, Bukhari NI (2005) A survey on medicine prices availability, affordability and price components in Malaysia using the WHO/HAI methodology [Online]. Malaysia. Accessed 5 Dec 2012
  5. Babar ZUD, Ibrahim MIM, Singh H, Bukahri NI, Creese A (2007) Evaluating drug prices, availability, affordability, and price components: implications for access to drugs in Malaysia. PLoS Med 4:e82CrossRefGoogle Scholar
  6. Bahri S (2013) Use of health economics data in listing and pricing of pharmaceuticals: Ministry of Health perspective. Monash Health Economic Forum 2013. Monash University Malaysia, Bandar Sunway.Google Scholar
  7. Bahrom S (2013) Robust growth seen for healthcare industry [Online]. Accessed 11 June 2013
  8. Bridel A (2012) Explaining 1 care: its proposals, rationale and feasibility. Accessed 17 Aug 2012
  9. Business Monitor International (2013) Malaysia pharmaceuticals and healthcare report Q3 2013. Business Monitor International Ltd., LondonGoogle Scholar
  10. Central Bank of Malaysia (2013) Exchange rate [Online]. Accessed 23 Oct 2013
  11. Chua GN, Hassali MA, Shafie AA, Awaisu A (2010) A survey exploring knowledge and perceptions of general practitioners towards the use of generic medicines in the northern state of Malaysia. Health Policy 95:229–235CrossRefGoogle Scholar
  12. Director General of Health Malaysia (1997) Essential Drugs Concept- An International Perspective [Online]. Accessed 26 Nov 2013
  13. Employees Provident Fund (2013) About EPF [Online]. Accessed 27 Jan 2014
  14. Gan BZ (2013) Say no to inducement to medical prescribers [Online]. Accessed 25 Nov 2013
  15. Haas JS, Phillips KA, Gerstenberger EP, Seger AC (2005) Potential savings from substituting generic drugs for brand-name drugs: medical expenditure panel survey, 1997–2000. Ann Intern Med 142:891–897CrossRefGoogle Scholar
  16. Hassali MA, Yuen KH, Ibrahim MIM, Wong JW, Ng BH, San Ho DS (2009) Malaysian pharmaceutical industry: opportunities and challenges. J Generic Med 6:246–252CrossRefGoogle Scholar
  17. Hassali MA, Shafie AA, Al-Haddad M, Balamurugan T, Awaisu A, Siow Y (2010) A qualitative study exploring the impact of the pharmaceutical price war among community pharmacies in the state of Penang, Malaysia. J Clin Diagn Res 4:3161–3169Google Scholar
  18. Hassali MA, Shafie AA, Babar ZUD, Khan TM (2012) A study comparing the retail drug prices between Northern Malaysia and Australia. J Pharm Health Serv Res 3:103–107CrossRefGoogle Scholar
  19. Hassali MA, Tan CS, Saleem F, Aljadhey H (2013) A qualitative exploration of perceptions toward pharmaceutical price war among community pharmacists in the state of Penang, Malaysia. J Med Mark Device Diagn Pharm Mark 13:44–53CrossRefGoogle Scholar
  20. Hassali MA, Alrasheedy AA, Ab Razak BA, Al-Tamimi SK, Saleem F, Haq NU, Aljadhey H (2014) Assessment of general public satisfaction with public healthcare services in Kedah, Malaysia. Australas Med J 7:35CrossRefGoogle Scholar
  21. Hussain SH (2008) Drug control and formulary management in Malaysia. Value Health 11:S158–S159CrossRefGoogle Scholar
  22. International Network of Agencies for Health Technology Assessment (INAHTA) (2014) MaHTAS—Health Technology Assessment Section, Ministry of Health Malaysia [Online]. Accessed 22 April 2014
  23. Jaafar S, Noh KM, Muttalib KA, Othman NH, Healy J, Maskon K, Abdullah AR, Zainuddin J, Bakar AA, Rahman SSA, Ismail F, Yuen CY, Baba N, Said ZM (2013) Malaysia health system review. Health Syst Transit [Online] 3(1):103.
  24. Kamat VR, Nichter M (1998) Pharmacies, self-medication and pharmaceutical marketing in Bombay, India. Soc Sci Med 47:779–794CrossRefGoogle Scholar
  25. Kanavos P (2007) Do generics offer significant savings to the UK National Health Service? Curr Med Res Opin 23:105–116CrossRefGoogle Scholar
  26. Karim SA, Pillai G, Ziqubu-Page T, Cassimjee M, Morar M (1996) Potential savings from generic prescribing and generic substitution in South Africa. Health Policy Plan 11:198–202CrossRefGoogle Scholar
  27. King DR, Kanavos P (2002) Encouraging the use of generic medicines: implications for transition economies. Croat Med J 43:462–469Google Scholar
  28. Kolassa E (1997) Prices politic, and problems—a pricing philosophy. J Pharm Mark Pract 1:21–27CrossRefGoogle Scholar
  29. Mahmood M, Bukhari N (2002) Pharmaceutical management and marketing. Tariq Academy, Faisalabad, pp 115–144Google Scholar
  30. Malaysia Competition Commission (2010) Competition Act 2010 [Online]. Accessed 20 Dec 2012
  31. Malaysia External Trade Development Corporation (2013) Pharmaceutical: overview of the industry [Online]. Accessed 18 Aug 2013
  32. Malaysian Association of Pharmaceutical Suppliers (MAPS) (2014) Message from the President, June 2014 [Online]. Accessed 4 Aug 2014
  33. Malaysian Pharmaceutical Society, Malaysian Community Pharmacy Guild (2013) Community pharmacy pricing issues and strategies required. Accessed 19 Nov 2013
  34. Malaysian Industrial Development Authority (2011) Guide on pharmaceutical industry in Malaysia. Accessed 3 Feb 2013
  35. Malaysian Medical Resource (2012) National Pharmaceutical Formulary 2012 [Online]. Accessed 26 Nov 2013
  36. Malaysian Pharmaceutical Society (2012) An “honest-voice” against unethical promotion [Online]. MPS Announcements, Articles and News Alerts. Accessed 15 Dec 2012
  37. Malaysian-German Chamber of Commerce and Industry (2011) “Market Watch 2012” The healthcare sector in Malaysia. Accessed 24 April 2014
  38. Ministry of Finance Malaysia (2013) Malaysia government procurement regime. Accessed 23 Oct 2013
  39. Ministry of Health Malaysia (2005) Malaysian statistics on medicine 2005 [Online]. Accessed 19 July 2014
  40. Ministry of Health Malaysia (2007) Malaysian National Medicines Policy. Accessed 24 April 2014
  41. Ministry of Health Malaysia (2008a) Malaysia’s health [Online]. Accessed 20 July 2014
  42. Ministry of Health Malaysia (2008b) Malaysia’s health 2008. Accessed 6 Nov 2012
  43. Ministry of Health Malaysia (2012a) Malaysian National Medicines Policy. Accessed 12 Sept 2014
  44. Ministry of Health Malaysia (2012a) Malaysian National Medicines Policy. Accessed 24 April 2014
  45. Ministry of Health Malaysia (2012b) Pharmacoeconomic guideline for Malaysia [Online]. Accessed 28 Nov 2013
  46. Ministry of Health Malaysia (2013) Health facts 2013. Accessed 18 Aug 2013
  47. Ministry of Health Malaysia (2014) Outpatient charges [Online]. Accessed 14 Jan 2014
  48. National Pharmaceutical Control Bureau (2012a) About the Drug Control Authority [Online]. Accessed 13 Dec 2012
  49. National Pharmaceutical Control Bureau (2012b) Drug registration guidance document. Accessed 13 Dec 2012
  50. Ngadiman SA (2013) Financing ARV experience from Malaysia [Online]. Accessed 26 Nov 2013
  51. Oorjitham S (2011) Competition countdown: level playing field [Online]. New Straits Times. Accessed 15 Dec 2012
  52. Performance Management Delivery Unit (2012) Healthcare [Online]. Accessed 5 March 2014
  53. Performance Management Delivery Unit (2013a) About economic transformation program (ETP) [Online]. Accessed 21 Nov 2013
  54. Performance Management Delivery Unit (2013b) Healthcare NKEA fact sheet. Accessed 23 Nov 2013
  55. Performance Management Delivery Unit (2013c) National Key Economic Area (NKEA): health care [Online]. Accessed 23 Nov 2013
  56. Pharmaceutical Services Division Ministry of Health Malaysia (2012a) Malaysian National Medicines Policy [Online]. Accessed 21 July 2014
  57. Pharmaceutical Services Division Ministry of Health Malaysia (2012b) Pharmacoeconomic guideline for Malaysia, p 33.
  58. Shafie AA, Hassali MA (2008) Price comparison between innovator and generic medicines sold by community pharmacies in the state of Penang, Malaysia. J Generic Med 6:35–42CrossRefGoogle Scholar
  59. Sivalal S (2009) Health technology assessment in Malaysia. Int J Technol Assess Health Care 25:224–230CrossRefGoogle Scholar
  60. Social Security Association. Medical benefit [Online]. Accessed 27 Jan 2014
  61. Tandon A, Murray CJ, Lauer JA, Evans DB (2000) Measuring overall health system performance for 191 countries [Online]. Accessed 11 June 2013
  62. Wong ZY, Hassali MA, Alrasheedy AA, Saleem F, Yahaya AH, Aljadhey H (2014) Malaysian generic pharmaceutical industries: perspective from healthcare stakeholders. J Pharm Health Serv Res. doi: 10.1111/jphs.12072
  63. World Health Organization (2011) System of Health Accounts (SHA 2011) [Online]. Accessed 20 Nov 2013

Copyright information

© Springer International Publishing Switzerland 2015

Authors and Affiliations

  1. 1.Discipline of Social and Administrative Pharmacy, School of Pharmaceutical SciencesUniversiti Sains MalaysiaMindenMalaysia
  2. 2.Pharmacy DepartmentHospital Teluk IntanTeluk IntanMalaysia

Personalised recommendations